Results of a randomized trial of the neuroprotectant drug riluzole in patients with so-called "Parkinson plus syndromes" of multiple system atrophy and progressive supranuclear palsy show no effect on survival vs placebo.
Medscape Medical News
Susan Jeffrey
More...